The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission.

J Crohns Colitis

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Published: September 2015

Background And Aims: Symptoms compatible with irritable bowel syndrome (IBS) are common in patients with ulcerative colitis (UC) in clinical remission. It has been suggested that these symptoms might arise due to post-inflammatory changes comparable with post-infectious IBS. The aim was to study factors at new onset of UC that predict development of IBS-like symptoms during clinical remission.

Methods: In total, 98 patients with new onset of UC were followed prospectively for 3 years with yearly follow-up visits. Data from the first visit at the onset of UC were compared between a group of patients who fulfilled the criteria for IBS while in remission (UCR+IBS) during follow-up and a group who did not (UCR-IBS).

Results: Among the UC patients, 87 met the criteria for clinical remission and 25 (29%) of these reported IBS-like symptoms in remission during follow-up. There was no difference in inflammatory disease activity at the initial flare or in the prevalence of previous IBS symptoms when comparing UCR+IBS and UCR-IBS patients. The UCR+IBS patients reported more severe gastrointestinal symptoms, including abdominal pain, during their primary flare.

Conclusion: The severity and extent of inflammation at onset of UC do not seem to affect the development of IBS-like symptoms in UC patients during clinical remission. The high prevalence of IBS-like symptoms is not explained by pre-existing IBS. UCR+IBS patients reported more severe gastrointestinal symptoms at disease onset, which might indicate a more sensitive gastrointestinal tract in this category of patients.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjv107DOI Listing

Publication Analysis

Top Keywords

ibs-like symptoms
20
clinical remission
16
symptoms
10
patients
9
inflammation onset
8
ulcerative colitis
8
symptoms clinical
8
development ibs-like
8
ucr+ibs patients
8
patients reported
8

Similar Publications

Background And Purpose: Irritable bowel syndrome (IBS) is a common condition that is challenging to treat, and novel drugs are needed for this condition. Previously, a chronic vicarious social defeat stress (cVSDS) mouse model exhibits IBS-like symptoms. Also agonists of the opioid δ-receptor exert anti-stress effects in rodents with minimal adverse effects.

View Article and Find Full Text PDF

Implication of the enteric glia in the IBS-like colonic inflammation associated with endometriosis.

BMC Womens Health

December 2024

Department of Basic Sciences - Physiology Division, Ponce Health Sciences University, Ponce Research Institute, PO Box 7004, Ponce, 00732-7004, PR, Puerto Rico.

Background: Endometriosis is a complex gynecological disorder characterized by the ectopic growth of endometrial tissue. Symptoms of endometriosis are known to impair the quality of life of patients, and among these are found dysmenorrhea, chronic pelvic pain, and gastrointestinal (GI) issues. GI issues such as painful bowel movements, bloating and constipation or diarrhea, are one of the common reasons for misdiagnosis with irritable bowel syndrome (IBS).

View Article and Find Full Text PDF

Irritable bowel syndrome (IBS) is a functional bowel disorder defined by recurrent abdominal pain, coupled with irregular bowel habits and alterations in the frequency as well as the consistency of stool. At present, IBS is considered as a disease of gut-brain interaction, and an increasing number of studies are focusing on the brain-gut axis. However, the brain regions associated with IBS have not been fully studied yet.

View Article and Find Full Text PDF
Article Synopsis
  • This clinical trial investigated how effective paroxetine and gabapentin are at improving gastrointestinal symptoms, mental health, and overall quality of life in patients with ulcerative colitis during remission.
  • A total of 97 patients were divided into two groups: one received paroxetine (20 mg/day) and the other gabapentin (100 mg increasing to 300 mg over three months), with assessments conducted over three months.
  • Results showed that patients taking paroxetine experienced significantly greater reductions in anxiety and depression, as well as improved quality of life, compared to those taking gabapentin.
View Article and Find Full Text PDF
Article Synopsis
  • * These IBS-like symptoms significantly reduce quality of life and lead to higher healthcare usage, making accurate diagnosis and treatment essential.
  • * A comprehensive approach is recommended for treatment, addressing not only inflammation but also including evidence-based pharmacological options, lifestyle changes, and consideration of psychological factors to improve overall patient care.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!